🔗 Share this article

Given that America undertakes unprecedented changes to its vaccine schedules, one figure has emerged somewhat surprisingly: Tracy Beth Høeg, a Danish American physician and public health researcher who initially gained attention by questioning COVID-19 vaccinations throughout the global health crisis and has zeroed in on alleged fatalities following Covid immunization in her recent position at the US Food and Drug Administration (FDA).

Proposed Shifts to Childhood Vaccine Schedule

Health officials had intended to announce sweeping changes to the pediatric vaccine schedule recently, aligning the US with Denmark’s vaccine program, according to reports – a significant shift that would put the US out of step with a large portion of the world with insufficient data for public health gain. The announcement has been delayed until the new year.

Rather than the director of the vaccine center, Høeg is listed to speak at the meeting. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth appointee to lead the center this calendar year.

A New Direction at the FDA

The acting appointment may indicate a closer partnership between the drug and vaccine branches as Høeg and Prasad consolidate power at the FDA – and it points to a greater focus upon dismantling long-standing immunizations at the FDA.

The new acting director has repeatedly called for discontinuing some childhood immunization guidelines in the US in order to be more like Denmark's approach, a society with universal health coverage and a citizenry approximately the population of the state of Wisconsin.

So far comments, she has kept her attention on vaccination policy – traditionally the domain of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Doubts Over Expertise

The appointee has no apparent track record in pharmaceutical research, approval processes or administrative roles, which has been standard for previous leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the commissioner and the vaccine center since earlier this year.

“It seems she lacks to have any of the qualifications” for overseeing the drug-regulation department, stated a neurologist and psychiatrist. “She lacks experience running a clinical trial. She has no expertise in managing a major agency. She has no expertise in drug approvals.”

Previous directors of the center would “grasp laws and regulations and the science of pharmaceutical innovation”, said a former acting FDA commissioner. “Frankly, she lacks the type of experience that previous people who ran the center have had.”

This division has an enormous workload at the agency, she stated.

“Everybody just pays attention on the novel medication approvals, but the off-patent medication office clears numerous off-brand pharmaceuticals. There’s a biologic copycat branch, OTC medication office and more, and every single one must be supervised,” Woodcock explained. “The area you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Additionally, a significant leadership element to the position, which oversees in excess of 5,000 staff members. “It’s a enormous leadership role, if you perform it correctly,” the former official said.

Agency Reaction and Contentious Programs

In response to concerns about Dr. Høeg's credentials and whether this appointment indicates increased cooperation among regulatory chiefs on vaccines, a press secretary stated that the “concerns are based on flawed assumptions”.

“Her resume matches the functions of her job,” the official stated, noting the months Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and approval science, including computerized risk analysis and shot safety tracking”.

As acting director, Dr. Høeg inherits the agency head's new priority voucher program, a controversial one-day drug-approval program that reportedly troubled her predecessors. “By what process are these drugs being selected for this voucher program? Who makes the choices?” Howard asked. “There’s a lot of secrecy happening at the regulatory body right now.”

In general, he stated, “the Food and Drug Administration seems to be moving towards laxer regulations of all drugs, except for shots.”

Documented Track Record on Vaccines

With vaccines, Høeg has a clearer, if concerning, past, some experts have noted. She authored a analysis using non-validated public submissions to assess the incidence of myocarditis after COVID-19 immunization. She counseled the state of Florida top health official Joseph Ladapo, who allegedly have changed statistics to suggest COVID-19 vaccines are more dangerous than they are.

Included in her “desired changes” for the new federal leadership featured revising regulations for novel immunizations and ending “unnecessary” immunizations, she remarked after the election on a audio program. At the agency, Høeg has reportedly suggested excluding adolescent males from getting Covid vaccines.

“She is an thorough dogmatist who commences with her preconceived notions and reverse-engineers to accommodate the science in a extremely misleading, untruthful manner,” Howard said.

Taking Control and a “Campaign of Retribution”

Dr. Høeg became part of fellow dissenters, {like|